ICER is developing a special report evaluating the evidence on apixaban (Eliquis®, Bristol Myers Squibb) and rivaroxaban (Xarelto®, Bayer) for the treatment of nonvalvular atrial fibrillation (NVAF). ICER plans to release this report in September 2023 and submit it to the Centers for Medicare and Medicaid Services (CMS) as part of the public comment process defined in CMS guidance.  The report will be tailored to reflect the legislative specifications in the Inflation Reduction Act and subsequent CMS guidance regarding the information that CMS will use to make initial offers and pursue drug price negotiation on selected drugs.   

Eliquis and Xarelto figure prominently among those drugs with high Medicare expenditure that are expected by many to be selected among the first group of drugs for price negotiation beginning later this year. 

Date of publication: September 2023

For more information, please contact Matt Seidner at